Activation of inflammasome components has been shown in patients with chronic liver injury, particularly NAFLD/NASH, and an NLRP3 selective inhibitor improved fibrosis in obese diabetic and NAFLD pathology mice (Sellin et al., 2015; Mridha et al., 2017). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.